EMDA® method is

EASY TO USE
FAST
SAFE
MINIMALLY INVASIVE
LIMITED SIDE-EFFECTS

Innovative treatment program for better clinical results and proven lower costs.

EMDA® INDICATIONS
- Non-Muscle Invasive Bladder Cancer
- Interstitial Cystitis
- Bladder Pain Syndrome
- Recurrent And Persistent UTI
- Hyperactive Bladder

EMDA® (ELECTROMOTIVE DRUG ADMINISTRATION)

Passive administration

EMDA® administration

EMDA® system from Physion Srl, is manufactured in Italy. The devices are in full compliance with all current European Medical Device Directives, with Class II Device CE-Mark.

EMDA® UTILIZES A SMALL ELECTRICAL CURRENT TO ACCELERATE AND DELIVER THE IONIZED DRUG MOLECULES INTO THE TISSUE BY ACTIVE TRANSPORT. THE RATE OF DRUG ADMINISTRATION IS FULLY CONTROLLABLE BY VARYING THE CURRENT INTENSITY.
In 2017 EMDA® treatment was included into the EAU (European urological guidelines) for the treatment for urinary bladder cancer

EMDA® is the most cost-effective device-assisted therapy, with low incidence of side effects, improved patient comfort, tolerance and efficacy.

**EMDA® (ELECTROMOTIVE DRUG ADMINISTRATION)**

**EMDA® Electromotive Drug Administration is an innovative and minimally invasive method** of enhancing local drug penetration across the urothelium of the bladder and prostatic urethra, resulting in greater quantities of local drug being delivered to a greater tissue depth than is achievable by passive diffusion alone, allowing a better clinical efficacy.

**EMDA® treatment helps to avoid many of the side effects** often associated with systemic administration.

---

**FUNCTIONAL UROLOGY - INDICATIONS**

**EMDA**

Electromotive Drug Administration is an innovative and minimally invasive method of enhancing local drug penetration across the urothelium of the bladder and prostatic urethra, resulting in greater quantities of local drug being delivered to a greater tissue depth than is achievable by passive diffusion alone, allowing a better clinical efficacy.

**EMDA® treatment helps to avoid many of the side effects** often associated with systemic administration.

**EMDA® Electromotive Drug Administration** is designed to provide the solutions to overcome the obstacles often associated with low rate passive diffusion and the inability to control the rate of administration.

**High-risk patients:**

A full sequential treatment program with BCG + EMDA-MMC

**High-Risk and Intermediate-Risk patients**

with superficial bladder cancer EMDA/MMC

**All patients:**

EMDA/MMC Pre-TURBT treatment

**INTERSTITIAL CYSTITIS**

Results show that the combination of EMDA treatment and bladder cystodistension is an effective first-line treatment in an outpatient setting.

**HYPERACTIVE BLADDER**

Treatment of hyperactive bladder with EMDA® system and oxybutynine plus other drugs in an outpatient setting.

**RECURRENT AND PERSISTENT UTI**

Treatment for urinary tract infections with EMDA system and antibiotics in an outpatient setting.

**BPS/IC**

Treatment of Bladder Pain Syndrome with EMDA® system and selected drugs to improve the quality of life to a selected group of patients in an outpatient setting.

**EMDA®** is the most cost-effective device-assisted therapy with low incidence of side effects, improved patient comfort, tolerance and efficacy.

---

**EMDA® (ELECTROMOTIVE DRUG ADMINISTRATION)**

**EMDA® INNOVATIVE PROGRAM FOR URINARY BLADDER CANCER TREATMENT (NMIBC)**

In 2017 EMDA® treatment was included into the EAU (European urological guidelines) for the treatment for urinary bladder cancer

**EMDA® is the most cost-effective device-assisted therapy, with low incidence of side effects, improved patient comfort, tolerance and efficacy.**